Page last updated: 2024-12-11
Uvangoletin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
uvangoletin: antineoplastic from Sarcandra glabra [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6483649 |
| CHEMBL ID | 4641401 |
| CHEBI ID | 180160 |
| SCHEMBL ID | 1938569 |
Synonyms (8)
| Synonym |
|---|
| 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylpropan-1-one |
| CHEBI:180160 |
| 1-(2,4-dihydroxy-6-methoxy-phenyl)-3-phenyl-propan-1-one |
| 1-propanone, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl- |
| uvangoletin |
| LMPK12120512 |
| SCHEMBL1938569 |
| CHEMBL4641401 |
Research Excerpts
Overview
Uvangoletin is a dihydrochalcone extracted from the traditional Chinese medicinal plant Sarcandra glabra.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Uvangoletin is a dihydrochalcone extracted from the traditional Chinese medicinal plant Sarcandra glabra. " | ( Uvangoletin, extracted from Sarcandra glabra, exerts anticancer activity by inducing autophagy and apoptosis and inhibiting invasion and migration on hepatocellular carcinoma cells. Shen, J; Shi, Y; Wen, T; Wu, Z; Zhu, X, 2022) | 3.61 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " This study aims to test the hypothesis that Sarcandra glabra combined with lycopene protect rats from lipopolysaccharide (LPS) induced acute lung injury (ALI)." | ( Sarcandra glabra combined with lycopene protect rats from lipopolysaccharide induced acute lung injury via reducing inflammatory response. Chen, SB; Liu, TY, 2016) | 0.43 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| chalcones | A ketone that is 1,3-diphenylpropenone (benzylideneacetophenone), ArCH=CH(=O)Ar, and its derivatives formed by substitution. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1647668 | Antibacterial activity against Escherichia coli at 5 mM incubated for 18 hrs by AlamarBlue assay | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.19) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||